Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride
Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use
of Forodesine Hydrochloride